GAMBACORTI PASSERINI, CARLO
GAMBACORTI PASSERINI, CARLO
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
The ALK gene, an attractive target for inhibitor development
2011 Tartari, C; Scapozza, L; GAMBACORTI PASSERINI, C
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors
2011 af Gennäs, G; Mologni, L; Ahmed, S; Rajaratnam, M; Marin, O; Lindholm, N; Viltadi, M; GAMBACORTI PASSERINI, C; Scapozza, L; Yli Kauhaluoma, J
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells
2012 Mologni, L; Brussolo, S; Ceccon, M; GAMBACORTI PASSERINI, C
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
2013 Piazza, R; Valletta, S; Winkelmann, N; Redaelli, S; Spinelli, R; Pirola, A; Antolini, L; Mologni, L; Donadoni, C; Papaemmanuil, E; Schnittger, S; Kim, D; Boultwood, J; Rossi, F; Gaipa, G; DE MARTINI, G; di Celle, P; Jang, H; Fantin, V; Bignell, G; Magistroni, V; Haferlach, T; Pogliani, E; Campbell, P; Chase, A; Tapper, W; Cross, N; GAMBACORTI PASSERINI, C
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
2013 Mologni, L; Redaelli, S; Morandi, A; Plaza Menacho, I; GAMBACORTI PASSERINI, C
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
2013 Ceccon, M; Mologni, L; Bisson, W; Scapozza, L; GAMBACORTI PASSERINI, C
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy
2011 GAMBACORTI PASSERINI, C; Piazza, R
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
2013 Cortes, J; Kim, D; Pinilla Ibarz, J; le Coutre, P; Paquette, R; Chuah, C; Nicolini, F; Apperley, J; Khoury, H; Talpaz, M; Dipersio, J; Deangelo, D; Abruzzese, E; Rea, D; Baccarani, M; Müller, M; GAMBACORTI PASSERINI, C; Wong, S; Lustgarten, S; Rivera, V; Clackson, T; Turner, C; Haluska, F; Guilhot, F; Deininger, M; Hochhaus, A; Hughes, T; Goldman, J; Shah, N; Kantarjian, H
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter
2014 Redaelli, S; Perini, P; Ceccon, M; Piazza, R; Rigolio, R; Boschelli, F; Giannoudis, A; GAMBACORTI PASSERINI, C
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
2013 Kantarjian, H; Cortes, J; Kim, D; Khoury, H; Brümmendorf, T; Porkka, K; Martinelli, G; Durrant, S; Leip, E; Kelly, V; Turnbull, K; Besson, N; GAMBACORTI PASSERINI, C
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex
2013 Piazza, R; Magistroni, V; Mogavero, A; Andreoni, F; Ambrogio, C; Chiarle, R; Mologni, L; Bachmann, P; Lock, R; Collini, P; Pelosi, G; GAMBACORTI PASSERINI, C
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia
2015 GAMBACORTI PASSERINI, C; Donadoni, C; Parmiani, A; Pirola, A; Redaelli, S; Signore, G; Piazza, V; Malcovati, L; Fontana, D; Spinelli, R; Magistroni, V; Gaipa, G; Peronaci, M; Morotti, A; Panuzzo, C; Saglio, G; Usala, E; Kim, D; Rea, D; Zervakis, K; Viniou, N; Symeonidis, A; Becker, H; Boultwood, J; Campiotti, L; Carrabba, M; Elli, E; Bignell, G; Papaemmanuil, E; Campbell, P; Cazzola, M; Piazza, R
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
2014 GAMBACORTI PASSERINI, C; Cortes, J; Lipton, J; Dmoszynska, A; Wong, R; Rossiev, V; Pavlov, D; Gogat Marchant, K; Duvillié, L; Khattry, N; Kantarjian, H; Brümmendorf, T
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B
2006 Aloisi, A; Di Gregorio, S; Stagno, F; Guglielmo, P; Mannino, F; Sormani, M; Bruzzi, P; GAMBACORTI PASSERINI, C; Saglio, G; Venuta, S; Giustolisi, R; Messina, A; Vigneri, P
An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase
2005 Gunby, R; Tartari, C; Porchia, F; Donella Deana, A; Scapozza, L; GAMBACORTI PASSERINI, C
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation
2007 Coluccia, A; Vacca, A; Dunach, M; Mologni, L; Redaelli, S; Bustos, V; Benati, D; Pinna, L; GAMBACORTI PASSERINI, C
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib
2005 Piazza, R; Magistroni, V; Gasser, M; Andreoni, F; Galietta, A; Scapozza, L; GAMBACORTI PASSERINI, C
Prognostic variables in patients with chronic myeloid leukemia treated with imatinib
2006 GAMBACORTI PASSERINI, C
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al
2005 Piazza, R; Magistroni, V; Franceschino, A; GAMBACORTI PASSERINI, C
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
2007 Neviani, P; Santhanam, R; Oaks, J; Eiring, A; Notari, M; Blaser, B; Liu, S; Trotta, R; Muthusamy, N; GAMBACORTI PASSERINI, C; Druker, B; Cortes, J; Marcucci, G; Chen, C; Verrills, N; Roy, D; Caligiuri, M; Bloomfield, C; Byrd, J; Perrotti, D